RPC
GILD icon

Rossmore Private Capital’s Gilead Sciences GILD Stock Holding History

Rossmore Private Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Buy
3,000
+200
+7% +$26.4K 0.03% 243
2026
Q1 		$390K Buy
2,800
+400
+17% +$56K 0.03% 227
2025
Q4 		$295K Buy
+2,400
New +$292K 0.03% 249

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rossmore Private Capital's GILD Position: Q2 2026 in Review

Rossmore Private Capital reduced its Gilead Sciences (GILD) stake by 1% in Q2 2026, selling an estimated $6.59K and leaving 4,732 shares worth $598K. The position accounts for 0.05% of the portfolio, ranked #196.

Rossmore Private Capital first reported a position in GILD in Q4 2017 and has held it in 22 quarters since. The position peaked at $692K in Q4 2022. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Rossmore Private Capital held 4,732 shares of Gilead Sciences worth $598K as of Q2 2026.
  • Rossmore Private Capital sold 50 Gilead Sciences shares in Q2 2026, an estimated $6.59K.
  • Gilead Sciences made up 0.05% of Rossmore Private Capital's portfolio in Q2 2026, its #196 holding.
  • Rossmore Private Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 22 quarters since.
  • Rossmore Private Capital's Gilead Sciences position peaked at $692K in Q4 2022.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Rossmore Private Capital's 13F filing for Q2 2026, filed 31 Jul 2026.